Carbapenem-Resistant Gram-Negative Fermenting and Non-Fermenting Rods Isolated from Hospital Patients in Poland—What Are They Susceptible to?

Brauncajs, Małgorzata; Bielec, Filip; Macieja, Anna; Pastuszak-Lewandoska, Dorota

doi:10.3390/biomedicines10123049

Cited by 5 publications

(4 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The tested strains came from the same collection described in the authors' previous publication [4]. The group of tested bacteria consisted of 50 K. pneumoniae, 7 E. coli, 15 P. aeruginosa, and 26 A. baumannii.…”

Section: Resultsmentioning

confidence: 99%

“…Drug susceptibility was determined on a standard Mueller-Hinton Agar (Thermo Fisher Scientific, Waltham, MA, USA) and incubated for 18 ± 2 h at 35 ± 1 • C following the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines [3]. The ability of all studied strains to produce carbapenemases was assessed and confirmed as described previously [4].…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

In Vitro Activity of Eravacycline against Carbapenemase-Producing Gram-Negative Bacilli Clinical Isolates in Central Poland

et al. 2023

Self Cite

View full text Add to dashboard Cite

Eravacycline is a novel antibiotic of the tetracycline class with activity against a broad spectrum of clinically significant bacteria, including multi-drug-resistant organisms. For this reason, it may be an alternative to treating critical infections of this etiology. We aimed to assess the in vitro effectiveness of eravacycline to carbapenemase-producing Gram-negative bacilli clinical isolates identified in hospitals in Łódź, Poland. We analyzed 102 strains producing KPC, MBL, OXA-48, GES, and other carbapenemases. Eravacycline susceptibility was determined following the EUCAST guidelines. The highest susceptibility was found in KPC (73%) and MBL (59%) strains. Our results confirmed in vitro the efficacy of this drug against carbapenem-resistant strains. However, eravacycline has been indicated only for treating complicated intra-abdominal infections, significantly limiting its use. This aspect should be further explored to expand the indications for using eravacycline supported by evidence-based medicine. Eravacycline is one of the drugs that could play a role in reducing the spread of multidrug-resistant microorganisms.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

In Vitro Activity of Eravacycline against Carbapenemase-Producing Gram-Negative Bacilli Clinical Isolates in Central Poland

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…Different studies recorded the upsurge in the spread of carbapenemase production among Grampositive and Gram-negative bacteria, and our results found that 68% of our isolates were resistant strains producing carbapenemase. Isolates included Staphylococcus hominis, Raoultella ornithinolytica, Enterobacter aurogenes, Klebsiella pneumoni and Acinetobacter bomani with a 100% CFR; the World Health Organization (WHO) classified such resistant strains as "a bacteria of critical priority" with an expected increase in the death rate due to infection in 2050 from 700,000 to 10 million per year (Takano et al, 2009;Brauncajs et al, 2022;Moubareck and Halat, 2022).…”

Section: Resultsmentioning

confidence: 99%

The emergence of antibiotic-induced resistant microbiomes among severe COVID-19-infected patients correlates with a high case fatality rate

Alshami, Z.,

Jiham, H.,

Alshammari, A.

2024

MJM

View full text Add to dashboard Cite

Aims:The coronavirus disease 2019 (COVID-19) is a contagious respiratory disease. The massive use of antibiotics during COVID-19 treatment induced the problem of antibiotic resistance among different strains of microbiome. The current study was conducted to evaluate the level of antibiotic resistance among pathogenic and microbiome bacteria isolated from the blood and upper respiratory tract of COVID-19 patients and its correlation with the case fatality rate in each patient. Methodology and results: COVID-19 patients were diagnosed using real-time reverse transcription-polymerase chain reaction (RT-PCR) technique. Swabs and blood samples were collected from each patient to isolate bacteria and every isolate identification was performed using the bioMérieux VITEK® 2 system. The case fatality rate among the study group was 50% for patients whose isolates were highly antibiotic-resistant. Blood culture was positive in 2.5% compared to nasal swab culture in 65%. Results of nasal swab culture revealed growth of Gram-positive bacteria isolated from 17.1% of patients, Gram-negative isolates were found in 9.75% and fungal isolates formed 9.75%. Most of the isolates were reflective of normal microbiomes; unfortunately, isolates were 100% resistant to penicillins, cephalosporins, azithromycin and amoxicillin-clavulanate. On the other hand, isolates were 100% sensitive to daptomycin. Conclusion, significance and impact of study: Results were alarming and there is a need to take measures to prevent the increase in bacterial resistance to antibiotics and limit the excessive use of it. It is crucial to monitor the rise in fungal infections among patients and consider it a risk factor for increasing the case fatality rate.

show abstract

“…Carbapenemases are a diverse collection of enzymes capable of inactivating select antibiotics from the β-lactam group (e.g., penicillins, cephalosporins, carbapenems). In Poland, the most prevalent carbapenemases present in bacteria isolated from infections are within the Metallo-β-lactamases (MBL) family with the majority being the New Delhi MBL (NDM) [ 3 , 4 ]. MBLs, in particular, are problematic because they can inactivate all classes of β-lactams except monobactams (of which aztreonam is the only substance currently approved for use in humans) and amidinopenicillins (of which mecillinam is in use for the treatment of urinary tract infections).…”

Section: Introductionmentioning

confidence: 99%

Aztreonam Combinations with Avibactam, Relebactam, and Vaborbactam as Treatment for New Delhi Metallo-β-Lactamase-Producing Enterobacterales Infections—In Vitro Susceptibility Testing

Brauncajs,

Bielec,

Malinowska

et al. 2024

Pharmaceuticals

Self Cite

View full text Add to dashboard Cite

Antimicrobial resistance is a major global health issue. Metallo-β-lactamases (MBL), in particular, are problematic because they can inactivate all classes of β-lactams except aztreonam. Unfortunately, the latter may be simultaneously inactivated by serine β-lactamases. The most dangerous known MBL is New Delhi Metallo-β-lactamase (NDM). This study aimed to test the in vitro susceptibility to aztreonam in combination with novel β-lactamase inhibitors (avibactam, relebactam, and vaborbactam) in clinical strains of Enterobacterales NDM which is resistant to aztreonam. We investigated 21 NDM isolates—including Klebsiella pneumoniae, Escherichia coli, and Citrobacter freundii—which are simultaneously resistant to aztreonam, ceftazidime/avibactam, imipenem/relebactam, and meropenem/vaborbactam. MICs for aztreonam combinations with novel inhibitors were determined using the gradient strip superposition method. The most effective combination was aztreonam/avibactam, active in 80.95% strains, while combinations with relebactam and vaborbactam were effective in 61.90% and 47.62%, respectively. In three studied strains, none of the studied inhibitors restored aztreonam susceptibility. Aztreonam/avibactam has the most significant antimicrobial potential for NDM isolates. However, combinations with other inhibitors should not be rejected in advance because we identified strain susceptible only to tested combinations with inhibitors other than avibactam. Standardization committees should, as soon as possible, develop official methodology for antimicrobial susceptibility testing for aztreonam with β-lactamase inhibitors.

show abstract

Carbapenem-Resistant Gram-Negative Fermenting and Non-Fermenting Rods Isolated from Hospital Patients in Poland—What Are They Susceptible to?

Cited by 5 publications

References 43 publications

In Vitro Activity of Eravacycline against Carbapenemase-Producing Gram-Negative Bacilli Clinical Isolates in Central Poland

In Vitro Activity of Eravacycline against Carbapenemase-Producing Gram-Negative Bacilli Clinical Isolates in Central Poland

The emergence of antibiotic-induced resistant microbiomes among severe COVID-19-infected patients correlates with a high case fatality rate

Aztreonam Combinations with Avibactam, Relebactam, and Vaborbactam as Treatment for New Delhi Metallo-β-Lactamase-Producing Enterobacterales Infections—In Vitro Susceptibility Testing

Contact Info

Product

Resources

About